It turns out that IDH-mutant glioma patients generally manifest low IGFBP2 expression, which is associated with improved survival independent of IDH mutational status, whereas high IGFBP2 expression results in worse survival than in the IDH-wildtype group. This evidence concerns the gene IDH2 and central nervous system cancer.